Induction chemotherapy for non-small cell lung cancer with clinically evident mediastinal node metastases: The role of postoperative radiotherapy Journal Article

  

Authors:	Armstrong, J. G.; Martini, N.; Kris, M. G.; Harrison, L. B.
Article Title:	Induction chemotherapy for non-small cell lung cancer with clinically evident mediastinal node metastases: The role of postoperative radiotherapy
Abstract:	Survival for clinical Stage IIIa (T1-3, N2) non-small cell lung cancer is very poor because of poor local disease control and systemic spread. To address these shortcomings, we initiated a treatment program with induction chemotherapy, surgery, and postoperative radiation reserved for patients with residual disease at thoracotomy. Between 1984 and 1986, 41 patients with clinically evident N2 disease were treated with induction chemotherapy followed by resection and the selective use of intraoperative brachytherapy. All patients with tumor in the resection specimen received two cycles of chemotherapy and 15 patients received radiation therapy. With a median follow-up of 5.4 years, overall survival is 27% at 3 years, and 12% at 5 years. Despite the adverse selection process median survival is 19 months for patients receiving postoperative radiation therapy, and 22 months for the more favorable patients not requiring radiation therapy, supporting the selective use of postoperative radiation in this setting. In summary, this treatment has yielded good median survival and long-term survival for some of the patients. However, the ultimate value of this approach can only be determined by prospective trials which compare it to standard therapy. © 1992.
Keywords:	adult; cancer survival; clinical article; controlled study; aged; survival rate; histopathology; neutropenia; cisplatin; cancer combination chemotherapy; multimodality cancer therapy; combined modality therapy; cancer staging; lymph node metastasis; lymphatic metastasis; phase 2 clinical trial; thoracotomy; carcinoma, non-small-cell lung; lung neoplasms; lorazepam; lung cancer; dexamethasone; radiation injury; vinblastine; survival time; brachytherapy; mitomycin c; vindesine; mediastinal neoplasms; metoclopramide; induction chemotherapy; intravenous drug administration; mediastinum lymph node; diphenhydramine; middle age; postoperative radiation; human; male; female; priority journal; article; n2 lung cancer
Journal Title:	International Journal of Radiation Oncology, Biology, Physics
Volume:	23
Issue:	3
ISSN:	0360-3016
Publisher:	Elsevier Inc.
Date Published:	1992-01-01
Start Page:	605
End Page:	613
Language:	English
DOI:	10.1016/0360-3016(92)90018-d
PUBMED:	1319427
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026634791&doi=10.1016%2f0360-3016%2892%2990018-D&partnerID=40&md5=3d09e12b698358632177530e3ce9aafb
Notes:	Article -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/149767